Mol Cancer Ther (2025) 24 (10_Supplement): B004.
Cancer Res (2023) 83 (8_Supplement): LB031.
You do not currently have access to this content.
Cancer Res (2025) 85 (8_Supplement_2): CT112.
Abstract. Mutations in PI3Kα lead to constitutive activation of the PI3K/AKT/mTOR pathway and are highly prevalent in cancer. PI3KαH1047R is the most common amino acid substitution mutation and ...
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio ® (avelumab), a ...
This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license. This work is licensed under a Creative Commons Attribution 4.0 International ...
Cancer Res (2024) 84 (3_Supplement_2): B031.
Abstract. Immunotherapy has transformed cancer treatment but remains ineffective in many solid tumors, largely due to the immunosuppressive tumor microenvironment (TME). A dense/stiff extracellular ...
Although significant progress has been made in systemic treatments, pancreatic cancer (PC) still remains the fourth leading cause of cancer-related deaths in the United States with an estimated 42,470 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results